Clinical trial NCT06715462: Efficacy and Safety of the N0750 Compared to Monotherapies in the Treatment of Painful Diabetic Peripheral Neuropathy
Official title: A Phase 3, Prospective, Adaptive, Randomized, Double-blind, Triple-masked, Parallel, Multicenter Clinical Trial to Evaluate the Efficacy and Safety of the N0750 Compared to Monotherapies in the Treatment of Painful Diabetic Peripheral Neuropathy
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: PHASE3
Conditions: Painful Diabetic Peripheral Neuropathy (PDPN)
Keywords: Diabetes Mellitus
Diabetes Mellitus, Type 1
Diabetes Mellitus, Type 2
Diabetes
Diabetes, Type 1
Diabetes, Type 2
Pain
diabetics
peripheral diabetic neuropathy
diabetic neuropathy peripheral
diabetic peripheral neuropathy
peripheral neuropathy
Peripheral Nervous System Diseases
peripheral
peripheral neuropathies
Peripheral nerve damage
neuropathies
neuropathy
PDPN
Lead sponsor: Eurofarma Laboratorios S.A.
Sponsor class: INDUSTRY
First posted: 2024-12-04
Enrollment: 666
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: A phase 3, prospective, adaptive, randomized, multicenter, double-blind, triple-masked, parallel clinical trial to evaluate the efficacy and safety of N0750 in relieving pain associated with painful diabetic peripheral neuropathy (PDPN).

Detailed description: The objective of this clinical trial is to demonstrate the superiority of treatment with N0750 compared to monotherapy with Cymbalta® (duloxetine hydrochloride 60 mg, delayed-release capsule) and Lyrica® (pregabalin 150 mg, hard capsule, given twice daily for a total daily dose of 300 mg).

The clinical trial population will consist of patients of both sexes, diagnosed with PDPN for at least 3 months, confirmed by the presence of signs and symptoms in the Neuropathic Impairment Score (NIS) and Neuropathic Symptom Score (NSS), respectively, and with pain ≥ 6 points on the Numerical Scale (11 points \[0-10\]).

The primary objective of this clinical trial is to evaluate the reduction in pain intensity associated with Diabetic Peripheral Neuropathy (DPN). The primary endpoint of the trial is the change from baseline (Randomisation Visit \[RV\]) at the end of 12 weeks of treatment (Visit 4) in the weekly mean pain intensity in the last 24 hours, as assessed by the Numerical Rating Scale (11 points \[0-10\]).

Eligibility criteria: Inclusion Criteria:

1. Ability to confirm voluntary participation and agree to all purposes of the trial, by signing and dating the Informed Consent Form (ICF) in two copies.
2. Subjects of both sexes, aged between 18 and 80 years.
3. Previous diagnosis of type 1 diabetes mellitus or type 2 diabetes mellitus.
4. Subjects diagnosed with PDPN for at least 3 months, confirmed by NSS ≥ 5 points and NIS ≥ 3 points.
5. Subjects who agree to discontinue current PDPN treatment during the washout period.
6. Subjects willing and able to comply with all study requirements, including completion of study diary and questionnaires.

Exclusion Criteria:

1. Painful peripheral neuropathy due to other causes, e.g. B12 and/or folate deficiency and hypothyroidism.
2. Previous diagnosis of other types of pain not related to PDPN, which at the Investigator's discretion, may confound the assessment of clinical trial endpoints, such as, but not limited to: peripheral vascular disease (ischemic pain); neurological disorders unrelated to diabetic neuropathy (phantom pain due to limb amputation); other painful conditions (e.g., arthritis).
3. Skin changes in the PDPN area that may cause changes in sensitivity or preclude physical assessment, e.g.: plantar ulcer.
4. Subjects with any other clinically significant clinical or laboratory change that, at the opinion Investigator's opinion make the subject unsuitable for trial participation.
5. Subjects with depression undergoing drug treatment or subjects with severe depression.
6. Subjects with a history of angioedema.
7. Subjects with a previous diagnosis of class III or IV heart failure according to the New York Heart Association criteria.
8. History of seizures.
9. Recent (\<6 months) myocardial infarction.
10. Patients with increased intraocular pressure or who are at risk of closed-angle glaucoma.
11. Subjects at risk of suicide at the Investigator's discretion.
12. Prior treatment with chemotherapeutic agents that cause neuropathy, such as, but not limited to: platinum compounds (oxaliplatin, cisplatin and carboplatin) and taxanes (docetaxel and paclitaxel).
13. History of current alcohol or drug abuse or dependence.
14. Lack of response to prior treatment with pregabalin at doses ≥ 300 mg and/or duloxetine 60 mg.
15. Use of prohibited medications within 7 days prior to the Screening Visit or change in concomitant drugs within 30 days prior to the Screening Visit.
16. Use of prohibited concomitant medications that cannot be discontinued during participation in the clinical trial.
17. Subjects with any clinically significant condition, including serious psychiatric disorders, which at the Investigator's discretion make the subject unsuitable for trial participation.
18. History of any malignancy within the past 5 years, except successfully treated non-metastatic basal cell or squamous cell carcinoma of the skin.
19. Subjects who have participated in other clinical trials in the last 12 months, unless the investigator believes there may be a direct benefit to them.
20. Pregnant or breastfeeding female subjects or women of childbearing potential who do not agree to use contraception during the clinical trial.
21. Glycated hemoglobin ≥ 10.5%.
22. Subjects with severe renal impairment (estimated glomerular filtration rate based on creatinine by the CKD-EPI equation \< 30 mL/min) and/or with severe liver disease (Aspartate Aminotransferase and Alanine Aminotransferase twice the reference value).
23. Clinically significant cardiac arrhythmias, second- or third-degree heart block, or left bundle branch block on 12-lead electrocardiogram (ECG).

Primary outcomes:
measure: Evaluation of the efficacy of N0750 compared to Cymbalta® and Lyrica® in reducing pain intensity in patients with painful diabetic peripheral neuropathy
timeFrame: 84 days
Secondary outcomes:
measure: Evaluation of the efficacy of N0750 compared to Cymbalta® and Lyrica® in reducing pain in patients with painful diabetic peripheral neuropathy
timeFrame: 84 days
measure: Evaluation of the efficacy of N0750 compared to Cymbalta® and Lyrica® on subject perception of overall change in painful diabetic peripheral neuropathy
timeFrame: 84 days
measure: Evaluate the safety profile of N0750 compared to Cymbalta® and Lyrica®
timeFrame: 84 days
Other outcomes:
Locations:
city: Itapevi
country: Brazil
facility: Eurofarma Laboratórios S.A
state: São Paulo
Study officials:
References: